HTRA1 and neoplasm: We then used the QS trigger system for the tumor‐specific re‐expression of HTRA in the AISI strain (AIS‐pLuxI‐htrA, AISI‐H) to activate bacterial immunogenicity, thus successfully achieving the efficacy and biosafety of bacteria‐mediated antitumor therapy (Scheme1).